Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration

David T. Wong; Alan R. Berger; Serge Bourgault; John Chen; Kevin Colleaux; Alan F. Cruess; Ravi I. Dookeran; Danny Gauthier; Bernard Hurley; Michael A. Kapusta; Peter J. Kertes; Cynthia X. Qian; Arif Samad; Thomas Sheidow; James H. Whelan

doi:10.1159/000516108

Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration

David T. Wong, Alan R. Berger, Serge Bourgault, John Chen, Kevin Colleaux, Alan F. Cruess, Ravi I. Dookeran, Danny Gauthier, Bernard Hurley, Michael A. Kapusta, Peter J. Kertes, Cynthia X. Qian, Arif Samad, Thomas Sheidow, James H. Whelan

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

7 Citas (Scopus)

Resumen

These recommendations, produced by a group of Canadian retina experts, have been developed to assist both retina specialists and general ophthalmologists in the management of vision-threatening neovascular age-related macular degeneration (nAMD). The recommendations are based on published evidence as well as collective experience and expertise in routine clinical practice. We provide an update on practice principles for optimal patient care, focusing on identified imaging biomarkers, in particular retinal fluid, as well as current and emerging therapeutic approaches. Algorithms for delivering high-quality care and improving long-term patient outcomes are provided, with an emphasis on timely and appropriate treatment to preserve and maintain vision. In the context of nAMD, increasing macular fluid or leakage on fluorescein angiography (FA) may indicate disease activity regardless of its location. Early elimination of intraretinal fluid (IRF) is of particular relevance as it is a prognostic indicator of worse visual outcomes. Robust referral pathways for second opinion and peer-to-peer consultations must be in place for cases not responding to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.

Idioma original	English
Páginas (desde-hasta)	265-280
Número de páginas	16
Publicación	Ophthalmologica
Volumen	244
N.º	4
DOI	https://doi.org/10.1159/000516108
Estado	Published - sep. 1 2021

Nota bibliográfica

Funding Information:
The authors report the following details regarding affiliation or involvement in an organization or entity with a financial or nonfinancial interest in the subject matter or materials discussed in this article. D.T.W. is an investigator in active clinical trials for Novartis Pharmaceuticals Canada and Roche Canada, has received research funding from Bayer Canada, Novartis Pharmaceuticals Canada, and Roche Canada, and been a consultant for Alcon, Allergan, Bayer Canada, Bausch Health, Novartis Pharmaceuticals Canada, Roche Canada, Topcon Canada, and Zeiss; he also owns equity in ArcticDx. A.R.B. has been a consultant and received honoraria from Bayer Canada, Novartis Pharmaceuticals Canada, Roche Canada, and Allergan. S.B. has been a consultant for Allergan, Bayer Canada, and Novartis Pharmaceuticals Canada, and participated in clinical studies founded by Bayer Canada and Novartis Pharmaceuticals Canada. J.C. has been a consultant and advisory board member for Allergan, Bayer Canada, and Novartis Pharmaceuticals Canada, and received research support from Novartis Pharmaceuticals Canada and Bayer Canada. K.C. has been a consultant/advisory board member for Bayer Canada and Novartis Pharmaceuticals Canada, and received research support from Novartis Pharmaceuticals Canada. A.F.C. has received honoraria for his performance of consultant and speaking roles for both Novartis Pharmaceuticals Canada and Bayer Canada within the past year. R.I.D. has been a consultant/advisory board member, and received speaking honoraria from Novartis Pharmaceuticals Canada, Alcon, Bayer Canada, Allergan, and Bausch and Lomb. D.G. is a consultant and speaker for Novartis Pharmaceuticals Canada, Bayer Canada, and Allergan. B.H. has received speaker honorarium from Alcon, Novartis Pharmaceuticals Canada, Allergan, Nikon Canada, Bausch and Lomb Canada, and Bayer Canada, and been a paid advisory board member for Bayer Canada, Novartis Pharmaceuticals Canada, Allergan, and Alcon. M.A.K. has been a consultant for Novartis Pharmaceuticals Canada and Bayer Canada. P.J.K. has received research funding from Bayer Canada, Allergan, Novartis Pharmaceuticals Canada, and Roche Canada, and fellowship funding from Novartis Pharmaceuticals Canada and Bayer Canada; he has also participated in advisory boards for Novartis Pharmaceuticals Canada, Allergan, Roche Canada, and Bayer Canada, and scientific advisory boards for Novelty Nobility, and owns stock in Arctic Dx. C.X.Q. has been a consultant for Allergan, Bayer Canada, Novartis Pharmaceuticals Canada, and Bausch and Lomb. A.S. has been a consultant for and received research funding from Novartis Pharmaceuticals Canada and Bayer Canada. T.S. has been a consultant (study protocols for Peregrine and CANTREAT) for Novartis Pharmaceuticals Canada, has participated in advisory boards for Allergan, and is an investigator in active clinical trials for Roche Canada, Bayer Canada, Novartis Pharmaceuticals Canada, Allergan, and Chengdu Kanghoug Biotechnology. J.H.W. has received honoraria from Alcon, Novartis Pharmaceuticals Canada, and Bayer Canada, as well as a research grant from Novartis Pharmaceuticals Canada.

Publisher Copyright:
© 2021 S. Karger AG, Basel.

ASJC Scopus Subject Areas

Ophthalmology
Sensory Systems

PubMed: MeSH publication types

Journal Article
Review

Acceder al documento

10.1159/000516108

Otros archivos y enlaces

Citar esto

Wong, D. T., Berger, A. R., Bourgault, S., Chen, J., Colleaux, K., Cruess, A. F., Dookeran, R. I., Gauthier, D., Hurley, B., Kapusta, M. A., Kertes, P. J., Qian, C. X., Samad, A., Sheidow, T., & Whelan, J. H. (2021). Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 244(4), 265-280. https://doi.org/10.1159/000516108

Wong, DT, Berger, AR, Bourgault, S, Chen, J, Colleaux, K, Cruess, AF, Dookeran, RI, Gauthier, D, Hurley, B, Kapusta, MA, Kertes, PJ, Qian, CX, Samad, A, Sheidow, T & Whelan, JH 2021, 'Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration', Ophthalmologica, vol. 244, n.º 4, pp. 265-280. https://doi.org/10.1159/000516108

@article{38dfac64931b4f60bddbb9a3a4a80244,

title = "Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration",

abstract = "These recommendations, produced by a group of Canadian retina experts, have been developed to assist both retina specialists and general ophthalmologists in the management of vision-threatening neovascular age-related macular degeneration (nAMD). The recommendations are based on published evidence as well as collective experience and expertise in routine clinical practice. We provide an update on practice principles for optimal patient care, focusing on identified imaging biomarkers, in particular retinal fluid, as well as current and emerging therapeutic approaches. Algorithms for delivering high-quality care and improving long-term patient outcomes are provided, with an emphasis on timely and appropriate treatment to preserve and maintain vision. In the context of nAMD, increasing macular fluid or leakage on fluorescein angiography (FA) may indicate disease activity regardless of its location. Early elimination of intraretinal fluid (IRF) is of particular relevance as it is a prognostic indicator of worse visual outcomes. Robust referral pathways for second opinion and peer-to-peer consultations must be in place for cases not responding to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.",

author = "Wong, {David T.} and Berger, {Alan R.} and Serge Bourgault and John Chen and Kevin Colleaux and Cruess, {Alan F.} and Dookeran, {Ravi I.} and Danny Gauthier and Bernard Hurley and Kapusta, {Michael A.} and Kertes, {Peter J.} and Qian, {Cynthia X.} and Arif Samad and Thomas Sheidow and Whelan, {James H.}",

note = "Funding Information: The authors report the following details regarding affiliation or involvement in an organization or entity with a financial or nonfinancial interest in the subject matter or materials discussed in this article. D.T.W. is an investigator in active clinical trials for Novartis Pharmaceuticals Canada and Roche Canada, has received research funding from Bayer Canada, Novartis Pharmaceuticals Canada, and Roche Canada, and been a consultant for Alcon, Allergan, Bayer Canada, Bausch Health, Novartis Pharmaceuticals Canada, Roche Canada, Topcon Canada, and Zeiss; he also owns equity in ArcticDx. A.R.B. has been a consultant and received honoraria from Bayer Canada, Novartis Pharmaceuticals Canada, Roche Canada, and Allergan. S.B. has been a consultant for Allergan, Bayer Canada, and Novartis Pharmaceuticals Canada, and participated in clinical studies founded by Bayer Canada and Novartis Pharmaceuticals Canada. J.C. has been a consultant and advisory board member for Allergan, Bayer Canada, and Novartis Pharmaceuticals Canada, and received research support from Novartis Pharmaceuticals Canada and Bayer Canada. K.C. has been a consultant/advisory board member for Bayer Canada and Novartis Pharmaceuticals Canada, and received research support from Novartis Pharmaceuticals Canada. A.F.C. has received honoraria for his performance of consultant and speaking roles for both Novartis Pharmaceuticals Canada and Bayer Canada within the past year. R.I.D. has been a consultant/advisory board member, and received speaking honoraria from Novartis Pharmaceuticals Canada, Alcon, Bayer Canada, Allergan, and Bausch and Lomb. D.G. is a consultant and speaker for Novartis Pharmaceuticals Canada, Bayer Canada, and Allergan. B.H. has received speaker honorarium from Alcon, Novartis Pharmaceuticals Canada, Allergan, Nikon Canada, Bausch and Lomb Canada, and Bayer Canada, and been a paid advisory board member for Bayer Canada, Novartis Pharmaceuticals Canada, Allergan, and Alcon. M.A.K. has been a consultant for Novartis Pharmaceuticals Canada and Bayer Canada. P.J.K. has received research funding from Bayer Canada, Allergan, Novartis Pharmaceuticals Canada, and Roche Canada, and fellowship funding from Novartis Pharmaceuticals Canada and Bayer Canada; he has also participated in advisory boards for Novartis Pharmaceuticals Canada, Allergan, Roche Canada, and Bayer Canada, and scientific advisory boards for Novelty Nobility, and owns stock in Arctic Dx. C.X.Q. has been a consultant for Allergan, Bayer Canada, Novartis Pharmaceuticals Canada, and Bausch and Lomb. A.S. has been a consultant for and received research funding from Novartis Pharmaceuticals Canada and Bayer Canada. T.S. has been a consultant (study protocols for Peregrine and CANTREAT) for Novartis Pharmaceuticals Canada, has participated in advisory boards for Allergan, and is an investigator in active clinical trials for Roche Canada, Bayer Canada, Novartis Pharmaceuticals Canada, Allergan, and Chengdu Kanghoug Biotechnology. J.H.W. has received honoraria from Alcon, Novartis Pharmaceuticals Canada, and Bayer Canada, as well as a research grant from Novartis Pharmaceuticals Canada. Publisher Copyright: {\textcopyright} 2021 S. Karger AG, Basel.",

year = "2021",

month = sep,

day = "1",

doi = "10.1159/000516108",

language = "English",

volume = "244",

pages = "265--280",

journal = "Ophthalmologica",

issn = "0030-3755",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration

AU - Wong, David T.

AU - Berger, Alan R.

AU - Bourgault, Serge

AU - Chen, John

AU - Colleaux, Kevin

AU - Cruess, Alan F.

AU - Dookeran, Ravi I.

AU - Gauthier, Danny

AU - Hurley, Bernard

AU - Kapusta, Michael A.

AU - Kertes, Peter J.

AU - Qian, Cynthia X.

AU - Samad, Arif

AU - Sheidow, Thomas

AU - Whelan, James H.

N1 - Funding Information: The authors report the following details regarding affiliation or involvement in an organization or entity with a financial or nonfinancial interest in the subject matter or materials discussed in this article. D.T.W. is an investigator in active clinical trials for Novartis Pharmaceuticals Canada and Roche Canada, has received research funding from Bayer Canada, Novartis Pharmaceuticals Canada, and Roche Canada, and been a consultant for Alcon, Allergan, Bayer Canada, Bausch Health, Novartis Pharmaceuticals Canada, Roche Canada, Topcon Canada, and Zeiss; he also owns equity in ArcticDx. A.R.B. has been a consultant and received honoraria from Bayer Canada, Novartis Pharmaceuticals Canada, Roche Canada, and Allergan. S.B. has been a consultant for Allergan, Bayer Canada, and Novartis Pharmaceuticals Canada, and participated in clinical studies founded by Bayer Canada and Novartis Pharmaceuticals Canada. J.C. has been a consultant and advisory board member for Allergan, Bayer Canada, and Novartis Pharmaceuticals Canada, and received research support from Novartis Pharmaceuticals Canada and Bayer Canada. K.C. has been a consultant/advisory board member for Bayer Canada and Novartis Pharmaceuticals Canada, and received research support from Novartis Pharmaceuticals Canada. A.F.C. has received honoraria for his performance of consultant and speaking roles for both Novartis Pharmaceuticals Canada and Bayer Canada within the past year. R.I.D. has been a consultant/advisory board member, and received speaking honoraria from Novartis Pharmaceuticals Canada, Alcon, Bayer Canada, Allergan, and Bausch and Lomb. D.G. is a consultant and speaker for Novartis Pharmaceuticals Canada, Bayer Canada, and Allergan. B.H. has received speaker honorarium from Alcon, Novartis Pharmaceuticals Canada, Allergan, Nikon Canada, Bausch and Lomb Canada, and Bayer Canada, and been a paid advisory board member for Bayer Canada, Novartis Pharmaceuticals Canada, Allergan, and Alcon. M.A.K. has been a consultant for Novartis Pharmaceuticals Canada and Bayer Canada. P.J.K. has received research funding from Bayer Canada, Allergan, Novartis Pharmaceuticals Canada, and Roche Canada, and fellowship funding from Novartis Pharmaceuticals Canada and Bayer Canada; he has also participated in advisory boards for Novartis Pharmaceuticals Canada, Allergan, Roche Canada, and Bayer Canada, and scientific advisory boards for Novelty Nobility, and owns stock in Arctic Dx. C.X.Q. has been a consultant for Allergan, Bayer Canada, Novartis Pharmaceuticals Canada, and Bausch and Lomb. A.S. has been a consultant for and received research funding from Novartis Pharmaceuticals Canada and Bayer Canada. T.S. has been a consultant (study protocols for Peregrine and CANTREAT) for Novartis Pharmaceuticals Canada, has participated in advisory boards for Allergan, and is an investigator in active clinical trials for Roche Canada, Bayer Canada, Novartis Pharmaceuticals Canada, Allergan, and Chengdu Kanghoug Biotechnology. J.H.W. has received honoraria from Alcon, Novartis Pharmaceuticals Canada, and Bayer Canada, as well as a research grant from Novartis Pharmaceuticals Canada. Publisher Copyright: © 2021 S. Karger AG, Basel.

PY - 2021/9/1

Y1 - 2021/9/1

N2 - These recommendations, produced by a group of Canadian retina experts, have been developed to assist both retina specialists and general ophthalmologists in the management of vision-threatening neovascular age-related macular degeneration (nAMD). The recommendations are based on published evidence as well as collective experience and expertise in routine clinical practice. We provide an update on practice principles for optimal patient care, focusing on identified imaging biomarkers, in particular retinal fluid, as well as current and emerging therapeutic approaches. Algorithms for delivering high-quality care and improving long-term patient outcomes are provided, with an emphasis on timely and appropriate treatment to preserve and maintain vision. In the context of nAMD, increasing macular fluid or leakage on fluorescein angiography (FA) may indicate disease activity regardless of its location. Early elimination of intraretinal fluid (IRF) is of particular relevance as it is a prognostic indicator of worse visual outcomes. Robust referral pathways for second opinion and peer-to-peer consultations must be in place for cases not responding to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.

AB - These recommendations, produced by a group of Canadian retina experts, have been developed to assist both retina specialists and general ophthalmologists in the management of vision-threatening neovascular age-related macular degeneration (nAMD). The recommendations are based on published evidence as well as collective experience and expertise in routine clinical practice. We provide an update on practice principles for optimal patient care, focusing on identified imaging biomarkers, in particular retinal fluid, as well as current and emerging therapeutic approaches. Algorithms for delivering high-quality care and improving long-term patient outcomes are provided, with an emphasis on timely and appropriate treatment to preserve and maintain vision. In the context of nAMD, increasing macular fluid or leakage on fluorescein angiography (FA) may indicate disease activity regardless of its location. Early elimination of intraretinal fluid (IRF) is of particular relevance as it is a prognostic indicator of worse visual outcomes. Robust referral pathways for second opinion and peer-to-peer consultations must be in place for cases not responding to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.

UR - http://www.scopus.com/inward/record.url?scp=85114431127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114431127&partnerID=8YFLogxK

U2 - 10.1159/000516108

DO - 10.1159/000516108

M3 - Review article

C2 - 33823520

AN - SCOPUS:85114431127

SN - 0030-3755

VL - 244

SP - 265

EP - 280

JO - Ophthalmologica

JF - Ophthalmologica

IS - 4

ER -

Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto